Ultimé Premium NAD+ III Boost (Australia Biotechnology Group Pty Ltd)
Product Name
Ultimé Premium NAD+ III Boost
ARTG details
393959
Date of review outcome
Date cancellation takes effect
Date of publication
Jun-2026
Outcome
Medicine is no longer permitted to be supplied
Is it safe to continue using this medicine?
Yes, based on the sponsor's certification. However, use of this medicine may pose a safety risk for some people. Follow the recommended actions below.
What action should consumers take?
If pregnant or likely to become pregnant, consult a pharmacist or a doctor before use.
Consider whether this medicine is right for you based on this medicine potentially not working as expected in relation to boosting NAD+.
Be aware this medicine does not contain the ingredient NAD as implied by its name and advertising.
Consider whether this medicine is right for you based on this medicine potentially not working as expected in relation to boosting NAD+.
Be aware this medicine does not contain the ingredient NAD as implied by its name and advertising.
Review scope
Targeted (see Additional Information below)
Information reviewed
ARTG Record, Labels, Manufacturing Documentation, Website
Issues related to safety
The label for this medicine was missing the mandatory warning statement for nicotinic acid, as set out under 'What actions should consumers take?'. This warning statement is necessary to ensure the safe use of this medicine individuals who are pregnant or likely to become pregnant.
While this omission is unacceptable, the last batch of this medicine expired in August 2025. As such, this medicine is unlikely to pose an immediate risk to consumer health and safety.
While this omission is unacceptable, the last batch of this medicine expired in August 2025. As such, this medicine is unlikely to pose an immediate risk to consumer health and safety.
Issues related to efficacy
This medicine does not contain the ingredient NAD as implied by its name. Therefore, it may not work for claims related to NAD.
The labels and website for this medicine contained the claim specified in 'What action should consumers take?' above. However, these claims were not covered by the sponsor's certification that they held evidence to substantiate them.
The labels and website for this medicine contained the claim specified in 'What action should consumers take?' above. However, these claims were not covered by the sponsor's certification that they held evidence to substantiate them.
Actions taken during the review
The TGA required the sponsor to correct the issues with this medicine. The sponsor did not sufficiently address all the issues. The TGA cancelled this medicine and withdrew permission for further supply.
Grounds for cancellation
This medicine is not eligible for listing (paragraph 30(1A)(a) of the Act).
It appears to the Secretary that the presentation of the goods is unacceptable (paragraph 30(2)(aa) of the Act).
The goods do not conform to a standard applicable to the goods (paragraph 30(2)(e) of the Act).
It appears to the Secretary that the presentation of the goods is unacceptable (paragraph 30(2)(aa) of the Act).
The goods do not conform to a standard applicable to the goods (paragraph 30(2)(e) of the Act).
Additional information
This medicine was targeted to check its compliance in relation to claims about nicotinamide adenine dinucleotide (NAD, NAD+, NADH) or nicotinamide mononucleotide (NMN)